OREANDA-NEWS. Angle has announced results from a prostate cancer research study carried out by its KOL partner Barts Cancer Institute (BCI). The final data are yet to be published, but headline results indicate that Parsortix can potentially perform as well as or better than current standard of care in terms of detecting early-stage prostate cancer and assessing its severity, and can do so with a simple blood test. While this will require further clinical studies, it represents a likely second clinical application, in which Parsortix can substantially affect the management of cancer patients. 

The results are encouraging and we expect Angle will provide an update on the strategy for prostate cancer in the coming months, which may bring clarity about commercialisation. Once that is available, we will review our financial forecasts and the assumptions underlying our DCF-based valuation which, prior to adjustments for the new developments, is unchanged at ?95m or 161p/share. 

About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring that a global investor audience can access our investment knowledge.